2 recruiting, 1 completed. 2 Phase 1, 1 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Early Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow LMP744: new trials by email Literature Review of LMP744 trials Research Report on LMP744
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma LMP744, Conventional Surgery or Biopsy - Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Phase 1 / Phase 2 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2026-07-15 | 2026-10-16 |
| Medication Combinations of Dasatinib, Quercetin, Fisetin, Temozolomide, LMP744, and Autologous TLPO Vaccine for the Treatment of Previously Treated Glioma With Residual Disease Biospecimen Collection, Dasatinib, Fisetin - Glioma | Early Phase 1 | Recruiting | Mayo Clinic | 30 | 2025-08-12 | 2026-10-01 |
| Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas LMP744, Ondansetron, Olanzapine - Solid Tumors, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 36 | 2017-02-27 | 2024-12-10 |
Glioma (2) · Brain Neoplasms (1) · Central Nervous System Neoplasms (1) · Glioblastoma (1) · Lymphoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Nerve Tissue (1) · Recurrence (1)
Mayo Clinic (1) · National Cancer Institute (NCI) (1) · National Institute of Neurological Disorders and Stroke (NINDS) (1)
United States (3)
Alice P Chen, M.D. (1) · Sadhana Jackson, M.D. (1) · Terence C. Burns, MD, PhD (1)